Injectable medications belonging to the class of GLP-1 receptor agonists, commonly prescribed for the treatment of obesity and diabetes, have now been linked to a reduced risk of non-infectious uveitis, an inflammatory eye condition. This significant discovery was made by specialists at the Cole Eye Institute of the Cleveland Clinic, with their research findings published in the prestigious journal JAMA Ophthalmology.
Uveitis is an inflammation affecting the middle layer of the eye, which can also involve the retina. Symptoms include pain, redness, and a decline in vision. In severe instances, this condition can lead to irreversible vision loss. Globally, approximately four million new cases of uveitis are diagnosed each year.
An extensive analysis of data from over 516,000 patients revealed a compelling correlation: individuals who were taking GLP-1 medications had approximately a 50 percent lower risk of developing uveitis compared to those not using these drugs. This protective effect was observed consistently, irrespective of whether the patients had diabetes or not.
While traditional treatments for uveitis typically involve steroids or prolonged immunosuppressive therapy, these new results suggest that GLP-1 drugs may possess additional anti-inflammatory properties. This expanded understanding positions them as promising agents not only for managing weight and blood sugar levels but also for potentially safeguarding the eyes against inflammatory diseases.
It`s worth noting that in early August, specialists also reported a different, unexpected side effect associated with popular weight loss medications, including drugs like Ozempic. This research indicated that these medications could reduce muscle strength, even without a noticeable loss of overall muscle mass.
